<DOC>
	<DOC>NCT01604408</DOC>
	<brief_summary>LY2495655 is an investigational drug being tested for muscle wasting. Muscle wasting includes shrinking of the muscle and weakness. This can occur when a muscle is no longer as active as usual. When muscles are no longer in use, they become weaker.</brief_summary>
	<brief_title>A Study in Older Participants Who Have Fallen and Have Muscle Weakness</brief_title>
	<detailed_description />
	<mesh_term>Muscle Weakness</mesh_term>
	<mesh_term>Paresis</mesh_term>
	<criteria>Sustained at least 1 fall within 1 calendar year before study screening. Requires ≥12 seconds to perform a repeated chair stands test or is unable to complete this test at screening. Hand grip strength is ≤37 kilograms (kg) for men (81.4 pounds) or ≤21 kg for women (46.2 pounds) at screening. Can stand up from a chair and walk ≥10 meters without human assistance (gait aids are acceptable such as cane[s], crutches, or walker) at screening. Able to climb at least 1 step on a staircase without human assistance according to the participant at screening (using handrails is allowed). Have screening clinical laboratory test results within normal reference range for the population, or have results with acceptable deviations that are judged to be not clinically significant by the investigator. Major lower limb pain or neurologic impairment or vestibular vertigo or visual impairment that could severely confound measures of physical performance. Recent lower limb fracture and/or major lower limb surgery. Planned major surgical procedure within 6 months following study drug dosing. Have had a lower extremity amputation of the foot, leg, and/or thigh. Have a body mass index (BMI) ≥35 kg/m2. Severe vitamin D deficiency. Underlying muscle disease other than ageassociated muscle waste or disuse atrophy. Current use or previous use of any drugs known to influence muscle mass or performance. Have had a recent neurologic injury (&lt;6 months before study drug dosing) such as stroke or spinal cord injury. History of a malignant neoplasm in the 18 months before first study drug dosing. Have a history or presence of unstable cardiovascular or pulmonary comorbidities. Have a positive fecal occult blood (FOB) test at screening or the participant cannot provide a stool sample for FOB testing before first study drug dosing. Have either severe ongoing liver disease or aspartate aminotransferase (AST) or alanine aminotransferase (ALT) &gt;2 times upper limit of normal (ULN), or alkaline phosphatase (ALP) &gt;1.5 times ULN, or total bilirubin &gt;1.5 times ULN at screening. Have an estimated creatinine clearance &lt;20 mL/minute. Have a history of severe allergic reaction to a monoclonal antibody. Are males with a female partner of childbearing potential who do not agree to use contraception during the treatment period of the study and up to 15 weeks after the last dose of investigational product (study drug). Have known allergies to LY2495655, its constituents, or related compounds. Have severe active psychiatric disease or cognitive impairment MiniMental State Examination ([MMSE] &lt;24) making the participant unlikely to understand the informed consent form or comply with protocol procedures. Excessive consumption of alcohol or abuse of drugs. Have uncontrolled diabetes mellitus. Have had ocular trauma, ophthalmologic surgery, or eye laser treatment within 6 months before study drug dosing. Have hyponatremia (serum sodium levels &lt;135 millimoles/Liter (mmol/L) at screening unless a retest shows normonatremia before study drug dosing.</criteria>
	<gender>All</gender>
	<minimum_age>75 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2013</verification_date>
</DOC>